Connection

Co-Authors

This is a "connection" page, showing publications co-authored by JOHN FREDERICK DE GROOT and SHIAO-PEI WEATHERS.
Connection Strength

3.286
  1. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol. 2016 09; 129(3):487-494.
    View in: PubMed
    Score: 0.560
  2. VEGF Manipulation in Glioblastoma. Oncology (Williston Park). 2015 Oct; 29(10):720-7.
    View in: PubMed
    Score: 0.530
  3. Resistance to antiangiogenic therapy. Curr Neurol Neurosci Rep. 2014 May; 14(5):443.
    View in: PubMed
    Score: 0.481
  4. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab141.
    View in: PubMed
    Score: 0.201
  5. Potential neurologic and oncologic implications of the novel coronavirus. Neuro Oncol. 2020 07 07; 22(7):1050-1051.
    View in: PubMed
    Score: 0.184
  6. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.
    View in: PubMed
    Score: 0.182
  7. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
    View in: PubMed
    Score: 0.182
  8. Pre-surgical connectome features predict IDH status in diffuse gliomas. Oncotarget. 2019 Nov 05; 10(60):6484-6493.
    View in: PubMed
    Score: 0.176
  9. Are we AKT-ually getting closer to making targeted therapy successful in breast cancer brain metastases? Neuro Oncol. 2019 11 04; 21(11):1344-1345.
    View in: PubMed
    Score: 0.176
  10. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer. 2019 05; 112:83-93.
    View in: PubMed
    Score: 0.169
  11. Prospective Clinical Sequencing of Adult Glioma. Mol Cancer Ther. 2019 05; 18(5):991-1000.
    View in: PubMed
    Score: 0.169
  12. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma. CNS Oncol. 2016; 5(1):11-26.
    View in: PubMed
    Score: 0.134
  13. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad032.
    View in: PubMed
    Score: 0.056
  14. Aggressiveness of care at end of life in patients with high-grade glioma. Cancer Med. 2021 12; 10(23):8387-8394.
    View in: PubMed
    Score: 0.051
  15. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.